Clinical trials: Flavivirus Infections
Dengue
Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s)
The purpose of this study was to describe the neutralizing antibody response against each dengue serotype at 1 month post second dose of TDV or placebo in dengue-naive adolescent participants.
- Trial name
- NCT03341637
- Testing
- Tetravalent Dengue Vaccine (TDV)
- Where
- 5 sites in Mexico
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Takeda
Japanese Encephalitis
Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51
The study investigates the long term safety and immunogenicity of the Japanese Encephalitis vaccine IC51 up to month 60.
- Trial name
- NCT00596102
- Testing
- Japanese Encephalitis purified inactivated vaccine
- Volunteers
- 3,258 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Dengue
An Epidemiological Surveillance Study to Evaluate the Incidence of Dengue in Brazil
The purpose of this study is to estimate the incidence of dengue infection in children and adults in geographically distinct locations of Brazil.
- Trial name
- NCT01751139
- Testing
- Blood sample collection, Data collection
- Where
- 5 sites in Brazil
- Volunteers
- 3,300 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Japanese Encephalitis
Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea
The aim of this study was to document the immunogenicity and safety of a booster dose of IMOJEV administered at least 12 months after the primary dose.
- Trial name
- NCT01900444
- Testing
- IMOJEV
- Where
- 8 sites in South Korea
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Encephalitis, Japanese Encephalitis
Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.
The purpose of this study is to assess whether ChimeriVax™ JE vaccine (a new vaccine to be used for vaccination against Japanese encephalitis) is safe and well tolerated when compared to placebo (dummy) vaccination.
- Trial name
- NCT00314132
- Testing
- ChimeriVax-JE, Japanese Encephalitis vaccine, 0.9% Saline
- Where
- 22 sites in United States, Australia
- Volunteers
- 2,004 people, healthy volunteers welcome
- Sponsor
- Sanofi
Zika, Dengue
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
Background: Mosquitoes and similar insects called sand flies carry parasites that can cause diseases. These viruses and parasites can spread quickly and be difficult to control.
- Conditions
- Zika, Dengue, Malaria, Chikungunya
- Trial name
- NCT03641339
- Testing
- One vector feeding, Four vector feeding
- Where
- United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Japanese Encephalitis
Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects
The purpose of this study is to describe the immunogenicity and safety of IMOJEV® in adult and pediatric populations in Vietnam and serve a bridging study to compare immunogenicity, reactogenicity, and safety data obtained with…
- Trial name
- NCT02492165
- Testing
- Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)
- Where
- Vietnam
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Encephalitis, Japanese B
Determining Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine
This study will determine whether it is safe and effective to administer Japanese encephalitis (JE) live attenuated SA 14-14-2 vaccine at the same time as measles vaccine.
- Trial name
- NCT00249769
- Testing
- Live Japanese encephalitis vaccine SA 14-14-2 (LJEV), Measles Vaccine (MV)
- Where
- Philippines
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- PATH
Dengue Virus, Dengue Fever
Efficacy and Safety of Dengue Vaccine in Healthy Children
The primary objective of the study was to assess the efficacy of CYD dengue vaccine after three injections in preventing symptomatic virologically-confirmed dengue (VCD) cases, regardless of the severity, due to any of the four…
- Conditions
- Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever, Dengue Diseases
- Trial name
- NCT00842530
- Testing
- CYD Dengue Vaccine, Inactivated rabies virus vaccine
- Where
- Thailand
- Volunteers
- 4,002 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Japanese Encephalitis
Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51
The objective is to demonstrate equivalence of three IC51 batches in terms of Geometric Mean Titers for anti-JEV neutralizing antibody.
- Trial name
- NCT00594958
- Testing
- IC51
- Volunteers
- 639 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Dengue
Safety and Immunogenicity Study of a Dengue Virus DNA Vaccine
The purpose of this study is to exame the safety of a DNA vaccine against dengue-1.
- Trial name
- NCT00290147
- Testing
- D1ME100 (dengue-1 premembrane/envelope DNA vaccine)
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Dengue Fever
Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
The purpose of this study is to evaluate the equivalence of the lyophilized formulation of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) compared with the liquid formulation of TDV.
- Trial name
- NCT02193087
- Testing
- TDV Liquid Formulation 1, TDV Liquid Formulation 2, TDV IDT Lyophilized
- Where
- 7 sites in United States
- Volunteers
- 1,002 people, healthy volunteers welcome
- Sponsor
- Takeda
Zika Virus
A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas
This clinical study will evaluate the safety, tolerability, and reactogenicity of 2 dose levels of messenger RNA (mRNA)-1893 Zika vaccine in comparison to a placebo control in healthy participants who are flavivirus-seronegative…
- Trial name
- NCT04917861
- Testing
- mRNA-1893
- Where
- 11 sites in United States, Puerto Rico
- Volunteers
- 808 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Dengue Fever, Dengue Hemorrhagic Fever
Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia
The purpose of this study was to evaluate the safety and immunogenicity of Phase III lots of the CYD dengue vaccine in a pediatric population in Malaysia.
- Trial name
- NCT01254422
- Testing
- Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus
- Where
- 4 sites in Malaysia
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Sanofi
Japanese Encephalitis
Immunogenicity Study of the Japanese Encephalitis Vaccine IC51
The objective is to demonstrate the non-inferiority of the Japanese Encephalitis vaccine IC51 compared to JE-VAX in healthy subjects aged > or = 18 years
- Trial name
- NCT00604708
- Testing
- IC51, JE-VAX
- Volunteers
- 867 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Dengue
A Phase II Trial of a Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy Adults in Thailand
This descriptive study will evaluate the safety and immunogenicity of different formulations of the WRAIR dengue vaccine compared to a placebo.
- Trial name
- NCT00370682
- Testing
- T-DEN F17, T-DEN F-19
- Where
- Thailand
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Dengue Fever, Dengue Hemorrhagic Fever
Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule
The aim of the study was to assess and describe the booster effect of a CYD dengue vaccine dose administered 4 to 5 years after the completion of a 3-dose vaccination schedule.
- Trial name
- NCT02623725
- Testing
- CYD Dengue Vaccine (5-dose formulation)
- Where
- 5 sites in Brazil, Colombia and 3 more
- Volunteers
- 251 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Fever
Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose
The purpose of this study is to describe antibody persistence for each of the 4 dengue serotypes for up to 63 months after the first vaccination in the primary vaccination series for participants from parent trial DEN-315…
- Trial name
- NCT03999996
- Testing
- Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)
- Where
- 10 sites in United States, Mexico
- Volunteers
- 365 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue Fever, Dengue Hemorrhagic Fever
Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America
The aim of the study was to assess the efficacy of Sanofi Pasteur's CYD dengue vaccine in preventing symptomatic virologically-confirmed dengue cases for dengue-endemic areas of Latin America.
- Conditions
- Dengue Fever, Dengue Hemorrhagic Fever, Dengue
- Trial name
- NCT01374516
- Testing
- Live, attenuated, dengue serotype 1, 2, 3, 4 virus
- Where
- 22 sites in Brazil, Colombia and 3 more
- Volunteers
- 20,869 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Fever
A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults
The study is designed to afford a safety and immunogenicity assessment of three Tetravalent Dengue Virus-Purified Inactivated Vaccine(TDENV-PIV) vaccine candidates.
- Trial name
- DPIV-001 (NCT01666652)
- Testing
- 4 µg TDENV-PIV with Alum adjuvant, 1 µg TDENV-PIV with AS03B1 adjuvant, Phosphate buffered saline
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command